approves triple lung drug

  1. GlaxoSmithKline breathes easier as U.S. …

    DE: https://finance.yahoo.com/news/glaxosmithkline-breathes-easier-u...

    GlaxoSmithKline breathes easier as U.S ... Chief Executive Emma Walmsley sees the triple lung drug as one of three ... AT&T sinks after court approves its $ ...
  2. GlaxoSmithKline breathes easier as U.S. …

    DE: https://www.srnnews.com/glaxosmithkline-breathes-easier-as-u-s...

    GlaxoSmithKline breathes easier as U.S. approves triple lung drug. By Ben Hirschler LONDON (Reuters) – U.S. regulators have approved GlaxoSmithKline’s three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine despite falling sales of the older drug Advair.
  3. Europe approves GlaxoSmithKline's new

    DE: https://health.economictimes.indiatimes.com/news/pharma/europe...

    LONDON - Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair.
  4. GlaxoSmithKline breathes easier as U.S. …

    DE: https://www.reuters.com/article/us-gsk-copd-fda/glaxosmithkline...

    The drug is not indicated for asthma. GSK has been the respiratory market world leader since launching its Ventolin inhaler in 1969 and Walmsley, who took over as CEO in April, has made lung disease a continuing priority for the years ahead.
  5. GlaxoSmithKline breathes easier as U.S. …

    DE: http://wsau.com/news/articles/2017/...easier-as-us-approves-triple-lung-drug

    By Ben Hirschler LONDON (Reuters) - U.S. regulators have approved GlaxoSmithKline's three-in-one inhaler for chronic lung disease, a key new product for the group as ...
  6. Europe approves GlaxoSmithKline's new

    DE: https://www.reuters.com/article/us-gsk-lung/europe-approves...

    Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca and Novartis.
  7. Europe approves GlaxoSmithKline's new …

    DE: https://finance.yahoo.com/news/europe-approves-glaxosmithklines...

    Europe has approved GlaxoSmithKline's (GSK.L) new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory ...
  8. FDA approves GlaxoSmithKline’s triple

    DE: http://www.pharmalive.com/...breathes-easier-as-u-s-approves-triple-lung-drug

    LONDON (Reuters) – U.S. regulators have approved GlaxoSmithKline’s three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine despite falling sales of the older drug Advair.
  9. UPDATE 1-GlaxoSmithKline breathes …

    DE: http://www.businessinsider.com/r-update...us-approves-triple-lung-drug-2017-9

    * Trelegy Ellipta approved in U.S. for chronic lung disease * First once-daily single inhaler triple therapy for COPD * CEO sees it as one of three "critical" new ...
  10. UPDATE 1-GlaxoSmithKline breathes …

    DE: http://www.lse.co.uk › Reuters News

    UPDATE 1-GlaxoSmithKline breathes easier as U.S. approves triple lung drug. ... quarter of COPD patients are already using three drugs to control their lung ...